Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Business Impact

Scientific Whitewater

The Baltimore Case: A Trial of Politics, Science, and Character

Suspicions raised by biology postdoc Margot O’Toole about a few lines of data in a 1986 paper in the journal Cell by former MIT immunologist Thereza Imanishi-Kari, Nobel laureate David Baltimore and several co-workers snowballed into the late 20th century’s most public dispute over fraud and error in science. In 1991 The New York Times called it “A Scientific Watergate,” but a far more apt comparison is available today in the Whitewater investigation. Both the Baltimore saga and the Whitewater inquiry were pushed forward by obsessive, heavy-handed investigators with political agendas; both cases feature prominent targets who acted by turns indignant and contrite; and both matters dragged on interminably, with investigators chasing after details decreasingly related to the original alleged offenses. And just as the Whitewater inquiry long ago grew too convoluted for most citizens to grasp, the Baltimore case hinged on immunological experiments so arcane-and produced so many conflicting interpretations of the allegedly fabricated experimental records-that impartial observers rarely knew what to believe.

Daniel Kevles knows. An eminent historian of science at Caltech (where Baltimore was named president in 1997), Kevles not only examined Imanishi-Kari’s lab notebooks, which document the disputed experiments on the effect of gene transfers on antibody production in mice, but also waded through thousands of pages of testimony and interviewed more than 70 scientists and others caught up in the case, including all the principals. He concludes-as a Public Health Service appeals board did in 1996-that Imanishi-Kari is innocent of fakery. He also argues that Baltimore’s famously combative defense of Imanishi-Kari before muckraking Rep. John Dingell in 1989 congressional hearings was justified, if brash.

Kevles’ book is an opinionated and unsparing one. Kevles argues, for example, that O’Toole, criticized by Imanishi-Kari when she was unable to replicate parts of the gene transfer study, was guided largely by resentment and frustration over her own sputtering scientific career when she later charged that Imanishi-Kari had fudged the data from the original experiments. The scientifically sporting thing for O’Toole to do, he asserts, would have been to design new experiments to test competing hypotheses. “Baltimore…was right to contend that O’Toole’s critique of the Cell paper could be resolved not by argument but only by further research,” he observes. Kevles’ exhaustive critique of O’Toole’s charges and the way the government handled them, on the other hand, probably makes further research on what has gone down in history as “the Baltimore case” unnecessary.

Couldn't make it to EmTech Next to meet experts in AI, Robotics and the Economy?

Go behind the scenes and check out our video
More from Business Impact

How technology advances are changing the economy and providing new opportunities in many industries.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

/3
You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.